U.S. market Closed. Opens in 1 day 15 hours 16 minutes

KRTX | Karuna Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for KRTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong.

Valuation (14%)

Company Industry
P/E Ratio (TTM) -29.52 -22.08
PEG Ratio (TTM) 3.96 15.66
P/S Ratio (TTM) 19,264.95 49.38
P/B Ratio (TTM) 9.94 18.85
P/FCF Ratio (TTM) -32.41 -3.07
Price to 5YR AVG Earnings Ratio -51.94 -3.42
Price to 5YR AVG FCF Ratio -76.55 -9.04

Profitability (0%)

Company Industry
ROA (TTM) -31.60% -5.15%
ROE (TTM) -30.79% 16.37%
Net Profit Margin (TTM) -64,554.74% -2,030.32%
ROIC 5YR AVG -38.15% 15.65%

Growth (0%)

4QTR AVG 3YR AVG 5YR AVG
EPS -8.19% -64.24% -60.77%
Revenue -46.90% N/A -33.02%
Net Income -10.95% -106.24% -93.56%
Cash Flow -16.00% -90.47% -93.33%

Health (61%)

Company Industry
Current Ratio (TTM) 19.31 6.19
Quick Ratio (TTM) 18.61 5.91
D/E Ratio (TTM) 0.01 -15.10
Interest Coverage (TTM) N/A -1.60
Piotroski F-Score 1 5
Altman Z-Score 91.14 14.02
LTL to 5YR AVG FCF -0.08 0.18
Shares Outstanding Growth 5YR AVG 33.36% 123.85%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙